ArticleBMC nephrology2025
Impact of CRRT on graft outcomes in kidney transplantation from deceased donors with severe acute kidney injury.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundKidney transplantation (KT) is the preferred treatment for end-stage renal disease. However, challenges arise when using kidneys from deceased donors (DDs) with severe acute kidney injury (AKI). This study investigated the impact of continuous renal replacement therapy (CRRT) on graft outcomes in recipients of kidneys from DDs classified as acute kidney injury network (AKIN) stage 2 or 3.
methodsA retrospective analysis was conducted on patients who received kidneys from DDs managed at Korea University Anam and Guro Hospital between 2010 and 2020. Recipients were included if the donor had AKIN stage ≥ 2 AKI. They were categorized into three groups: AKIN 2, AKIN 3 without CRRT, and AKIN 3 with CRRT. Clinical characteristics and transplant outcomes, including delayed graft function (DGF), DGF duration, number of hemodialysis (HD) sessions, biopsy-proven acute rejection (BPAR), and graft survival, were compared among groups.
resultsDuring the study period, a total of 219 DDs were managed at our centers. Among them, 81 donors met the criteria for AKIN stage ≥ 2. From these donors, 81 recipients underwent KT, including 29 recipients who received kidneys from CRRT-treated donors. The incidence of DGF was the highest in the CRRT group (51.7%, P = 0.001). The CRRT group also required more HD sessions during the DGF period (2.6 ± 3.6 sessions vs. 1.6 ± 3.9 sessions, P = 0.001), although the CRRT group had a numerically shorter DGF duration than the non-CRRT AKIN 3 group (11.5 ± 6.9 days vs. 14.2 ± 8.7 days). The number of HD sessions was greater in the CRRT group, suggesting a more proactive perioperative support approach. BPAR rates were not significantly different across groups. One-year graft failure occurred in 5.0%, 3.1%, and 6.9% of recipients in AKIN 2, AKIN 3 non-CRRT, and AKIN 3 CRRT groups, respectively. Death-censored graft loss did not occur in any groups.
conclusionsAlthough CRRT was associated with a higher incidence of DGF, it might facilitate earlier recovery of graft function in recipients of kidneys from DDs with severe AKI. These findings support the use of kidneys from CRRT-treated donors, highlighting their potential to expand the donor pool without compromising one-year graft outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.